Ozempic or Mounjaro for weight loss: what the evidence actually says

The biggest misconception about this question

Most people searching 'Ozempic or Mounjaro' are really asking about semaglutide versus tirzepatide for weight loss. That's a completely reasonable question. The confusion arises because Ozempic became the name most associated with GLP-1 injections in the press, but Ozempic's UK licence covers type 2 diabetes management, not weight loss. The distinction between Ozempic and its weight-loss counterpart Wegovy matters legally and clinically: a prescriber cannot simply hand out Ozempic for weight management when a licensed option exists.

Wegovy is semaglutide at a 2.4mg maintenance dose, studied and approved specifically for obesity. If you've read about semaglutide producing roughly 15% average weight loss in clinical trials, that data comes from Wegovy's STEP 1 trial at 2.4mg, not from Ozempic's lower doses. The licensed comparison is therefore Mounjaro versus Wegovy, which is worth understanding properly.

If you want to go deeper on tirzepatide versus semaglutide at a mechanism level, there's more detail there. For now, the practical answer is this: in the UK, the legitimate options for weight management are Mounjaro and Wegovy.

How the two licensed medicines compare head-to-head

Mounjaro activates two receptors (GIP and GLP-1) while Wegovy acts on GLP-1 alone. In practice, both slow gastric emptying and reduce appetite, but tirzepatide's dual action appears to produce stronger effects on average. The SURMOUNT-1 trial reported average body-weight reductions of around 20–21% at the 15mg dose over 72 weeks, published in the New England Journal of Medicine. Wegovy's STEP 1 trial showed approximately 15% average loss over 68 weeks.

The SURMOUNT-5 trial then compared them directly. In that 72-week open-label study of adults with obesity and no diabetes, tirzepatide produced greater average weight reduction than semaglutide 2.4mg, the clearest head-to-head evidence available. NICE referenced this when appraising tirzepatide in TA1026.

The table below summarises the key factual differences.

A broader look at how Wegovy and Mounjaro compare across eligibility and results covers those nuances in more detail.

Side effects and tolerability: similar patterns, individual variation

Both medicines share a gastrointestinal side-effect profile, nausea, changes in bowel habit, indigestion, and fatigue are the most commonly reported. These tend to be most noticeable in the first few weeks or after a dose increase, and they often ease as the body adjusts. No medicine is risk-free, and if you feel unwell on treatment, contact your prescriber.

One thing worth knowing if you take the oral contraceptive pill: for Mounjaro specifically, UK guidance recommends adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase, because absorption of the pill may be reduced. NHS England sets this out in its guidance on weight-management injections. The equivalent evidence for semaglutide is less clear-cut.

The MHRA monitors both medicines closely. If you notice something unexpected, side effects can be reported at the Yellow Card scheme. A question our prescribers hear most weeks is whether one medicine is 'safer', the honest answer is that both carry a similar class of risk, and which suits a particular person depends on their full medical picture.

Which one can you actually get, and what's the right route?

We understand the frustration here. You've done the research, you know roughly what you want, and you'd like a straight answer. The truth is that neither Ozempic nor any other prescription medicine should be chosen on research alone, and that's not a dodge, it's the clinical reality.

Mounjaro and Wegovy are both available privately through a GPhC-registered pharmacy following a prescriber's assessment. Neither is available without a valid prescription. For most people, the question of which is better for weight loss, Mounjaro or Wegovy, comes down to individual health factors a prescriber works through with you.

If you're curious about how costs compare alongside the clinical picture, a breakdown of tirzepatide versus semaglutide on cost is worth reading. And for people wondering whether results favour one or the other in specific groups, there's nuance in who responds better to each. Which medicine suits you is a clinical decision our prescribers make with you, not an algorithm, not a search result. Check your eligibility to start that conversation.